Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck

• ClinicalTrials.gov Identifier: NCT02979977
• Recruitment Status: Recruiting
• First Posted: December 2, 2016
• Last Update Posted: January 11, 2023
• Sponsor: Yale University
• Collaborators: National Comprehensive Cancer Network; Boehringer Ingelheim
• Information provided by (Responsible Party): Yale University

Tracking Information

• First Submitted Date: November 29, 2016
• First Posted Date: December 2, 2016
• Last Update Posted Date: January 11, 2023
• Actual Study Start Date: March 24, 2017
• Estimated Primary Completion Date: December 2024 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: November 29, 2016)

Tumor shrinkage [ Time Frame: Disease progression or end of treatment (up to 2 years) ]

Objective Response Rate (Complete Response + Partial Response), defined by tumor shrinkage (mm), per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.

• Original Primary Outcome Measures: Same as current

Current Secondary Outcome Measures (submitted: November 29, 2016)

• Progression-free survival in weeks [ Time Frame: 1 year follow-up ]
  We will use Kaplan-Meier survival analysis to estimate the median PFS in the cohort.
• Overall survival in months [ Time Frame: 1 year follow-up ]
  Measured by a monthly phone calls. We will use Kaplan-Meier survival analysis to estimate the median and OS in the cohort.
• Duration of response in weeks [ Time Frame: 1 year follow-up ]
• Toxicity assessed with National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 [ Time Frame: Up to 2.5 years ]

• Original Secondary Outcome Measures: Same as current

Current Other Pre-specified Outcome Measures (submitted: November 29, 2016)

Exploratory biomarker analysis [ Time Frame: Up to 2 years ]

Analysis of tumor-tissue from biopsies obtained at baseline, after four weeks of treatment with the combination, and again at disease progression or end of treatment

• Original Other Pre-specified Outcome Measures: Same as current

Descriptive Information

• Brief Title: Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck
• Official Title: Single-Arm Phase II Trial of Dual Inhibition of EGFR With Afatinib and Cetuximab With Correlative Studies in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck
• Brief Summary: This is a single arm Phase II study for patients with recurrent or metastatic squamous cell carcinoma of the head and neck, who are previously treated with a platinum based regimen or with an immune checkpoint inhibitor. The primary objective is to evaluate the efficacy of the combination of cetuximab and afatinib.

Detailed Description

This study will be a multicenter, single-arm, open-label Phase II trial. Patients with advanced squamous cell carcinoma of the head and neck, who are previously treated with a platinum based regimen or with immune checkpoint inhibitor therapy or both, will be eligible for participation on the study. After a baseline evaluation and biopsy (where feasible), they will be treated with weekly/bi-weekly intravenous cetuximab and daily oral afatinib. Biopsy will be repeated where feasible after 4 weeks (window of +1 week) on therapy and again at disease progression or end of treatment.

Treatment will continue until disease progression or development of Grade 3 or higher drug related toxicities that fail to resolve to Grade 2 despite appropriate supportive care.

• Study Type: Interventional
• Study Phase: Phase 2
• Study Design: Allocation: N/A; Intervention Model: Single Group Assignment; Masking: None (Open Label); Primary Purpose: Treatment
• Condition: Squamous Cell Cancers of the Head and Neck

Intervention

• Drug: cetuximab
  30-60 minutes after the recommended pre-medications, cetuximab will be administered intravenously at a dose of 400mg/m2 on cycle 1, day 1 of treatment (loading dose) and at a dose of 250mg/m2 every 7 days (+/- 1 day) thereafter. Alternatively, patients can be treated at a dose of 500mg/m2 every 14 days (+/- 2 days).
  Other Name: Erbitux
• Drug: afatinib
  Patients will take a single oral dose of afatinib each day at a dose of 30 mg. Afatinib dose will not be escalated beyond the 30 mg daily oral dose; dose reductions of afatinib can occur to manage treatment related adverse events.
  Other Name: GIOTRIF or GILOTRIF

Study Arms

Experimental: All subjects

Advanced squamous cell carcinoma of the head and neck region, having previously been treated on a platinum based regimen or with an immune checkpoint inhibitor. Subjects will receive Afatinib dose 30 mg per day and weekly/bi-weekly intravenous cetuximab.

Interventions:

• Drug: cetuximab
• Drug: afatinib

• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Recruiting
• Estimated Enrollment (submitted: November 29, 2016): 50
• Original Estimated Enrollment: Same as current
• Estimated Study Completion Date: January 2025
• Estimated Primary Completion Date: December 2024 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

• Histologically confirmed squamous cell carcinoma of the head and neck that is metastatic, recurrent or locally advanced and not treatable with curative intent.
• Previous treatment with a platinum-based regimen or immune checkpoint inhibitor or both.2-week washout period prior to treatment start will be required.
• Patients who have experienced progression of disease within 6 months following completion of a platinum-based chemoradiation in the definitive or adjuvant setting will be permitted.
• Prior cetuximab permitted if it was given as part of multi-modality therapy for initial treatment of locally advanced disease.
• Measurable disease based on RECIST v 1.1. Baseline measurements and evaluations must be obtained within 4 weeks of enrollment. Disease in previously irradiated sites is considered measurable if there has been unequivocal disease progression or biopsy-proven residual carcinoma following radiation therapy.
• ECOG performance status ≤2
• Adequate organ function, defined as all of the following:
• Hemoglobin ≥ 8 g/dl.
• Absolute neutrophil count (ANC) ≥1000 / mm3.
• Platelet count ≥75,000 / mm3.
• Estimated creatinine clearance > 45ml / min.
• Total Bilirubin ≤ 1.5 times upper limit of (institutional/central) normal (Patients with Gilbert's syndrome total bilirubin must be ≤4 times institutional upper limit of normal).
• Aspartate amino transferase (AST) or alanine amino transferase (ALT) ≤ three times the upper limit of (institutional/central) normal (ULN) (if related to liver metastases ≤ five times ULN).
• Ability to understand and the willingness to sign a written informed consent that is consistent with ICH-GCP guidelines.
• Negative urine or serum pregnancy test for women of childbearing potential

Exclusion Criteria:

• Prior erlotinib, gefitinib or lapatinib therapy or prior exposure to any investigational EGFR or panErbB reversible or irreversible inhibitor or any prior panitumumab or investigational EGFR-directed monoclonal antibody.
• Radiotherapy within 2 weeks prior to enrollment. Palliative radiation to target organs may be allowed up to 2 weeks prior to enrollment, as long as there are other target lesions that can be monitored for response to study treatment.
• Known hypersensitivity to afatinib or its excipients
• Women of child-bearing potential (WOCBP) and men who are able to father a child, unwilling to be abstinent or use highly effective methods of birth control prior to study entry, for the duration of study participation and for at least 4 weeks after treatment has ended.
• Women who are pregnant, nursing, or who plan to become pregnant while in the trial.
• Any history of or concomitant condition that, in the opinion of the Investigator, would compromise the patient's ability to comply with the study or interfere with the evaluation of the efficacy and safety of the test drug.
• Concomitant malignancies at other sites that are being actively treated with systemic therapy
• Requiring treatment with any of the prohibited concomitant medications that cannot be stopped for the duration of trial participation.
• Clinically significant interstitial lung disease.
• Known history of untreated viral hepatitis or HIV.
• Patients with parenchymal brain metastases are not eligible, unless they have completed local therapy
• Leptomeningeal carcinomatosis

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 18 Years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Contacts

Contact: Cindy Voghell; 203-737-4784; cynthia.voghell@yale.edu

• Listed Location Countries: United States

Administrative Information

• NCT Number: NCT02979977
• Other Study ID Numbers: 1608018260
• Has Data Monitoring Committee: Yes

U.S. FDA-regulated Product

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No
• Product Manufactured in and Exported from the U.S.: No

IPD Sharing Statement

• Plan to Share IPD: No

• Current Responsible Party: Yale University
• Original Responsible Party: Aarti Bhatia, Yale University, Assistant Professor of Medicine
• Current Study Sponsor: Yale University
• Original Study Sponsor: Aarti Bhatia

Collaborators

• National Comprehensive Cancer Network
• Boehringer Ingelheim

Investigators

• Principal Investigator: Aarti Bhatia, MD, MPH; Yale University

• PRS Account: Yale University
• Verification Date: January 2023